Genentech
A Member of the Roche Group

Submitted by:
Oscar Merino, PharmD
US Medical Affairs
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080
Phone: (800) 821-8590
Email: genentechmedinfo-d@gene.com
Date of request: August 1, 2019
NCCN Guidelines Panel: B-Cell Lymphomas

NCCN B-Cell Lymphomas Panel:

Updated results from the Phase II GALEN study have been recently published.[1] As a follow-up to a previous submission dated December 6, 2018, please find enclosed a summary of this study, which was conducted to evaluate Gazyva® (obinutuzumab) in combination with lenalidomide for relapsed/refractory and advanced untreated follicular lymphoma.[1-2]

Requests:
Consider inclusion of Gazyva in combination with lenalidomide as a treatment option in both the first-line and second-line/subsequent therapy settings based on the results from the Phase II GALEN study.[1-2]

Rationale:
The GALEN study is an open label, multicenter, Phase Ib/II trial conducted to evaluate the efficacy and safety of Gazyva in combination with lenalidomide. This chemotherapy-free regimen was studied in patients with advanced untreated follicular lymphoma and in patients with relapsed/refractory follicular lymphoma (NCT01582776). Results are summarized below.

Relapsed/refractory follicular lymphoma:[1]
Morschhauser et al. recently published updated results for Gazyva in combination with lenalidomide in a cohort of 89 patients with relapsed/refractory follicular lymphoma. A total of 86 patients were assessable for efficacy. The primary endpoint was the proportion of patients who achieved an overall response at induction end.

At a median follow-up of 2.6 years, 79% of patients achieved an overall response (ORR) and 38% of patients achieved a complete response (CR) at induction end. At 2 years, event-free survival (EFS) was 62%, progression-free survival (PFS) was 65%, duration of response (DOR) was 70%, and overall survival (OS) was 87%.

The safety population included 88 patients who started induction therapy. The most common adverse events were asthenia (61%), neutropenia (43%), bronchitis (41%), diarrhea (40%), and muscle spasms (39%). The most common serious adverse events were basal cell carcinoma (6%), febrile neutropenia (5%), and infusion-related reactions (3%). Neutropenia was the most common toxicity of grade 3 or higher. A total of 57 serious adverse events were reported by 30 patients.

Advanced untreated follicular lymphoma:[2]
Please refer to a previous submission dated December 6, 2018 and enclosed reference for relevant data from the advanced untreated follicular lymphoma cohort in the GALEN study.

FDA Clearance:
- Gazyva in combination with lenalidomide is not an FDA-approved regimen.
- Gazyva is a CD20-directed cytolytic antibody indicated:
  - in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia

  - in combination with bendamustine followed by Gazyva monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen
  - in combination with chemotherapy followed by Gazyva monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma
- Please refer to the product prescribing information for the full FDA-approved indications and safety information, available at: http://www.gene.com/download/pdf/gazyva_prescribing.pdf

Thank you for your consideration and I hope this information is helpful to you. If you have any questions, please contact us at the phone number and email provided above.

Respectfully submitted,
Oscar Merino, PharmD

References:

1. Morschhauser F, Le gouill S, Feugier P, et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematol. 2019;6(8):e429-e437.
2. Morschhauser F, Salles G, Casasnovas, R, et al. A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untretated Follicular B-Cell Lymphoma in Need of Systemic Therapy. Oral presentation at: American Society of Hematology 60th ASH Annual Meeting & Exposition; December 1-4, 2018; San Diego, CA. Available at: http://www.bloodjournal.org/content/132/Suppl_1/446. Accessed August 1, 2019.